Definium (DFTX) CFO Brandi Roberts Receives Award

What Happened
Brandi Roberts, Chief Financial Officer of Definium Therapeutics (DFTX), was granted 62,500 performance share units (PSUs) on 2026-08-12. The award is recorded at $0.00 per share (total reported value $0) and represents the second tranche of PSUs; the shares remain contingent and subject to vesting and milestone achievement rather than an immediate open-market purchase.

Key Details

• Transaction date and type: 2026-08-12 — Grant/Award (code A). Reported price: $0.00 per share. Quantity: 62,500 PSUs.
• Shares owned after transaction: Not specified in the filing.
• Footnote (F1): These 62,500 common shares are the second tranche of PSUs granted effective June 2, 2025. They vest only with continued employment through June 2, 2028 and are contingent on specified clinical and regulatory milestones; each PSU is a contingent right to receive one common share upon achievement of those milestones.
• Filing timeliness: Filing date is 2026-08-12 (same date as the transaction reporting); no late filing indicated.

Context
Performance share units are contingent awards, not immediate stock ownership — they convert to actual shares only if service and performance conditions are met. Such awards are a common form of executive compensation and do not by themselves indicate an insider buying or selling stock; they reflect long-term incentive alignment tied to specific clinical/regulatory goals for the company.